RxDoctor Payments Data

Rachel Tierney, PA

Physician Assistant · Saratoga Springs, NYNPI 1225359540

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $52,300 of the $63,147 with a category attached, or 82.8%. Novo Nordisk accounts for 98.4% of it on its own, with 12 other manufacturers making up the rest. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$63,147in general payments, 2019–2025

Across 166 payments — averaging $380.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$62K
  • Lilly USA, LLC$319
  • Currax Pharmaceuticals LLC$166
  • Daiichi Sankyo Inc.$164
  • Phathom Pharmaceuticals, Inc.$154
  • Echosens North America, Inc.$34
  • plus $153 from 7 others

What the payments were for

  • Speaking & faculty fees$52,30083%
  • Travel & lodging$6,55410%
  • Food & beverage$4,2607%
  • Education$320%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,147 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$8,024
Medicare patients
71
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide124$151,497
MounjaroTirzepatide33$34,532
WegovySemaglutide14$17,907
Naltrexone Hcl47$3,176
Topiramate98$696
Metformin Hcl ErMetformin Hcl50$495
Bupropion Hcl SrBupropion Hcl27$418
Bupropion XlBupropion Hcl11$272
Omeprazole26$253
Famotidine20$225
Lisinopril11$7

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$62,157$169,404138 claims
Lilly USA, LLCMounjaro$319$34,53233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Saratoga Springs

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →